A ROR1–HER3–lncRNA Signalling Axis Modulates the Hippo–YAP Pathway to Regulate Bone Metastasis
Chunlai Li,Shouyu Wang,Zhen Xing,Aifu Lin,Ke Liang,Jian Song,Qingsong Hu,Jun Yao,Zhongyuan Chen,Peter K. Park,David H. Hawke,Jianwei Zhou,Yan Zhou,Shuxing Zhang,Han Liang,Mien-Chie Hung,Gary E. Gallick,Leng Han,Chunru Lin,Liuqing Yang
DOI: https://doi.org/10.1038/ncb3464
IF: 21.3
2017-01-01
Nature Cell Biology
Abstract:Bone metastases remain a serious health concern because of limited therapeutic options. Here, we report that crosstalk between ROR1–HER3 and the Hippo–YAP pathway promotes breast cancer bone metastasis in a long noncoding RNA-dependent fashion. Mechanistically, the orphan receptor tyrosine kinase ROR1 phosphorylates HER3 at a previously unidentified site Tyr1307, following neuregulin stimulation, independently of other ErbB family members. p-HER3 Tyr1307 recruits the LLGL2–MAYA–NSUN6 RNA–protein complex to methylate Hippo/MST1 at Lys59. This methylation leads to MST1 inactivation and activation of YAP target genes in tumour cells, which elicits osteoclast differentiation and bone metastasis. Furthermore, increased ROR1, p-HER3 Tyr1307 and MAYA levels correlate with tumour metastasis and unfavourable outcomes. Our data provide insights into the mechanistic regulation and linkage of the ROR1–HER3 and Hippo–YAP pathway in a cancer-specific context, and also imply valuable therapeutic targets for bone metastasis and possible therapy-resistant tumours. Li et al. show that ROR1–HER3 receptor tyrosine kinase signalling in breast cancer cells inhibits the MST1/2 Hippo pathway kinases through a lncRNA termed MAYA. The resulting activation of YAP promotes osteoclast differentiation for bone metastasis.